Which has preferable valuation and earnings, PGEN or IMVT?

Precigen has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 185.07 -$250.64M -$1.18 N/A Immunovant N/A N/A -$505.61M -$2.78 N/A

Is PGEN or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -646.99% 717.50% 58.48% Immunovant N/A -65.66% -59.88%

Does the media prefer PGEN or IMVT?

In the previous week, Immunovant had 9 more articles in the media than Precigen. MarketBeat recorded 11 mentions for Immunovant and 2 mentions for Precigen. Precigen's average media sentiment score of 1.30 beat Immunovant's score of 0.60 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RYTM or PGEN?

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Precigen. MarketBeat recorded 5 mentions for Rhythm Pharmaceuticals and 2 mentions for Precigen. Precigen's average media sentiment score of 1.30 beat Rhythm Pharmaceuticals' score of 1.14 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MIRM or PGEN?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Precigen. MarketBeat recorded 5 mentions for Mirum Pharmaceuticals and 2 mentions for Precigen. Mirum Pharmaceuticals' average media sentiment score of 1.53 beat Precigen's score of 1.30 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Precigen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PGEN or SYRE?

In the previous week, Spyre Therapeutics had 5 more articles in the media than Precigen. MarketBeat recorded 7 mentions for Spyre Therapeutics and 2 mentions for Precigen. Precigen's average media sentiment score of 1.30 beat Spyre Therapeutics' score of 0.85 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, LNTH or PGEN?

Lantheus has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.43 $233.56M $4.15 25.29 Precigen $9.68M 185.07 -$250.64M -$1.18 N/A

Is LNTH or PGEN more profitable?

Lantheus has a net margin of 18.05% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Lantheus' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Precigen -646.99% 717.50% 58.48%

Does the media favor LNTH or PGEN?

In the previous week, Lantheus had 4 more articles in the media than Precigen. MarketBeat recorded 6 mentions for Lantheus and 2 mentions for Precigen. Precigen's average media sentiment score of 1.30 beat Lantheus' score of 0.76 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Precigen (PGEN) Competitors

$5.03 +0.08 (+1.52%)

As of 10:56 AM Eastern

Compare

PGEN vs. IMVT, RYTM, MIRM, SYRE, and LNTH

Should you buy Precigen stock or one of its competitors? MarketBeat compares Precigen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Precigen include Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Spyre Therapeutics (SYRE), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does Precigen compare to Immunovant?

Precigen (NASDAQ:PGEN) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Precigen has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

In the previous week, Immunovant had 9 more articles in the media than Precigen. MarketBeat recorded 11 mentions for Immunovant and 2 mentions for Precigen. Precigen's average media sentiment score of 1.30 beat Immunovant's score of 0.60 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precigen has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	185.07	-$250.64M	-$1.18	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Immunovant has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Immunovant	N/A	-65.66%	-59.88%

Precigen currently has a consensus price target of $12.50, suggesting a potential upside of 148.76%. Immunovant has a consensus price target of $39.70, suggesting a potential downside of 0.79%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

33.5% of Precigen shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 41.4% of Precigen shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Precigen beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Precigen compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Precigen	-646.99%	717.50%	58.48%

33.5% of Precigen shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 41.4% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Rhythm Pharmaceuticals currently has a consensus price target of $138.29, suggesting a potential upside of 28.69%. Precigen has a consensus price target of $12.50, suggesting a potential upside of 148.76%. Given Precigen's higher probable upside, analysts plainly believe Precigen is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rhythm Pharmaceuticals has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, Precigen has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.

Rhythm Pharmaceuticals has higher revenue and earnings than Precigen. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	38.81	-$196.54M	-$3.13	N/A
Precigen	$9.68M	185.07	-$250.64M	-$1.18	N/A

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Precigen. MarketBeat recorded 5 mentions for Rhythm Pharmaceuticals and 2 mentions for Precigen. Precigen's average media sentiment score of 1.30 beat Rhythm Pharmaceuticals' score of 1.14 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Precigen beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Precigen compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Mirum Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Precigen has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.

33.5% of Precigen shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 41.4% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mirum Pharmaceuticals presently has a consensus price target of $143.40, indicating a potential upside of 20.62%. Precigen has a consensus price target of $12.50, indicating a potential upside of 148.76%. Given Precigen's higher probable upside, analysts plainly believe Precigen is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Mirum Pharmaceuticals has a net margin of -140.24% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Precigen	-646.99%	717.50%	58.48%

Mirum Pharmaceuticals has higher revenue and earnings than Precigen. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.91	-$23.36M	-$13.61	N/A
Precigen	$9.68M	185.07	-$250.64M	-$1.18	N/A

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Precigen. MarketBeat recorded 5 mentions for Mirum Pharmaceuticals and 2 mentions for Precigen. Mirum Pharmaceuticals' average media sentiment score of 1.53 beat Precigen's score of 1.30 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Precigen beats Mirum Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Precigen compare to Spyre Therapeutics?

Precigen (NASDAQ:PGEN) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

33.5% of Precigen shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Precigen currently has a consensus target price of $12.50, indicating a potential upside of 148.76%. Spyre Therapeutics has a consensus target price of $101.42, indicating a potential upside of 2.40%. Given Precigen's higher probable upside, equities research analysts clearly believe Precigen is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Spyre Therapeutics has lower revenue, but higher earnings than Precigen. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	185.07	-$250.64M	-$1.18	N/A
Spyre Therapeutics	$890K	9,786.34	-$155.20M	-$2.08	N/A

Spyre Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Precigen has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, Spyre Therapeutics has a beta of 3.02, suggesting that its stock price is 202% more volatile than the broader market.

In the previous week, Spyre Therapeutics had 5 more articles in the media than Precigen. MarketBeat recorded 7 mentions for Spyre Therapeutics and 2 mentions for Precigen. Precigen's average media sentiment score of 1.30 beat Spyre Therapeutics' score of 0.85 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spyre Therapeutics beats Precigen on 9 of the 17 factors compared between the two stocks.

How does Precigen compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Precigen has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Lantheus has a net margin of 18.05% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Lantheus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Precigen	-646.99%	717.50%	58.48%

99.1% of Lantheus shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Lantheus had 4 more articles in the media than Precigen. MarketBeat recorded 6 mentions for Lantheus and 2 mentions for Precigen. Precigen's average media sentiment score of 1.30 beat Lantheus' score of 0.76 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.43	$233.56M	$4.15	25.29
Precigen	$9.68M	185.07	-$250.64M	-$1.18	N/A

Lantheus currently has a consensus price target of $110.43, indicating a potential upside of 5.22%. Precigen has a consensus price target of $12.50, indicating a potential upside of 148.76%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Lantheus beats Precigen on 9 of the 16 factors compared between the two stocks.

Get Precigen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGEN vs. The Competition

Export

Metric	Precigen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.79B	$3.72B	$6.91B	$12.20B
Dividend Yield	N/A	2.20%	2.68%	8.87%
P/E Ratio	-4.26	21.46	27.23	23.90
Price / Sales	185.07	301.02	573.53	111.21
Price / Cash	N/A	146.26	49.25	59.89
Price / Book	83.75	8.40	10.85	6.19
Net Income	-$250.64M	$23.83M	$3.59B	$331.84M
7 Day Performance	-5.55%	-4.01%	-2.26%	-2.30%
1 Month Performance	6.24%	2.73%	1.89%	-1.63%
1 Year Performance	176.10%	43.29%	23.86%	16.11%

Precigen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGEN Precigen	2.9612 of 5 stars	$5.03 +1.5%	$12.50 +148.8%	+169.0%	$1.79B	$9.68M	N/A	190	Positive News
IMVT Immunovant	2.0403 of 5 stars	$38.60 -0.5%	$39.70 +2.8%	+118.8%	$7.96B	N/A	N/A	120	Gap Down
RYTM Rhythm Pharmaceuticals	3.047 of 5 stars	$111.68 -2.2%	$136.13 +21.9%	+16.0%	$7.82B	$189.76M	N/A	140	News Coverage Positive News
MIRM Mirum Pharmaceuticals	3.2623 of 5 stars	$121.91 -2.9%	$143.00 +17.3%	+122.3%	$7.66B	$521.31M	N/A	140	Positive News
SYRE Spyre Therapeutics	1.7949 of 5 stars	$88.74 +2.4%	$95.83 +8.0%	+481.0%	$7.62B	$890K	N/A	73

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGEN) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precigen (PGEN) Competitors

PGEN vs. IMVT, RYTM, MIRM, SYRE, and LNTH

How does Precigen compare to Immunovant?

Summary

How does Precigen compare to Rhythm Pharmaceuticals?

Summary

How does Precigen compare to Mirum Pharmaceuticals?

Summary

How does Precigen compare to Spyre Therapeutics?

Summary

How does Precigen compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precigen (PGEN) Competitors

PGEN vs. IMVT, RYTM, MIRM, SYRE, and LNTH

How does Precigen compare to Immunovant?

Which has more risk and volatility, PGEN or IMVT?

Does the media prefer PGEN or IMVT?

Which has preferable valuation and earnings, PGEN or IMVT?

Is PGEN or IMVT more profitable?

Do analysts recommend PGEN or IMVT?

Do insiders and institutionals hold more shares of PGEN or IMVT?

Summary

How does Precigen compare to Rhythm Pharmaceuticals?

Is RYTM or PGEN more profitable?

Do institutionals & insiders have more ownership in RYTM or PGEN?

Do analysts recommend RYTM or PGEN?

Which has more risk and volatility, RYTM or PGEN?

Which has preferable valuation & earnings, RYTM or PGEN?

Does the media favor RYTM or PGEN?

Summary

How does Precigen compare to Mirum Pharmaceuticals?

Which has more volatility and risk, MIRM or PGEN?

Do insiders and institutionals have more ownership in MIRM or PGEN?

Do analysts rate MIRM or PGEN?

Is MIRM or PGEN more profitable?

Which has stronger earnings and valuation, MIRM or PGEN?

Does the media refer more to MIRM or PGEN?

Summary

How does Precigen compare to Spyre Therapeutics?

Do insiders & institutionals believe in PGEN or SYRE?

Do analysts recommend PGEN or SYRE?

Which has higher valuation & earnings, PGEN or SYRE?

Is PGEN or SYRE more profitable?

Which has more volatility and risk, PGEN or SYRE?

Does the media prefer PGEN or SYRE?

Summary

How does Precigen compare to Lantheus?

Which has more risk and volatility, LNTH or PGEN?

Is LNTH or PGEN more profitable?

Do institutionals and insiders believe in LNTH or PGEN?

Does the media favor LNTH or PGEN?

Which has stronger earnings & valuation, LNTH or PGEN?

Do analysts rate LNTH or PGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools